Good news,,Procept is way ahead of the game,,,they have already passed the animal testing and have completed trials on sexually inactive women,, key phase 2 is nearing soon and the real story will unfold. Look at the attached quotes down below from the latest news on neuraths team and you already see how far ahead prct is,,Take note of the reference to dual use referred to by neurath regarding a possible contraceptive. Prct has already witnessed the inactivation of sperm in tests,, neurath is still assuming. I guarantee you Procept will be fast approaching a 20 dollar stock next year this time. the Brazilian market alone has been stated at 1 billion,, the whole world ,, can you imagine that.
Read the following excerpts from neurath first and then followed by
prct results
Neurath related press
(In studies in mice, the cream killed viruses and bacteria that cause sexually transmitted diseases, but did not kill bacteria such as lactobacilli found normally in the vagina.
Neurath's team assumes that it will inactivate sperm, although they did not test this.)
PRCT related press
Procept believes that its proprietary antimicrobial agent, PRO 2000, is ideally suited for use as a vaginal microbicide. PRO 2000 is a synthetic naphthalene sulfonate polymer of approximately 5,000 molecular weight. Its high water solubility and lack of color and odor make it well suited for topical use. Importantly, PRO 2000 Gel is straightforward to manufacture, allowing it to be produced for reasonable cost. It has also been shown to be highly stable, even under tropical conditions.
Studies conducted by several independent laboratories have shown that PRO 2000 is active against HIV-1 and HIV-2 in vitro. Isolates from both the developed and developing world are neutralized with comparable potency, and all susceptible cell types are protected. Mechanistic studies indicate that PRO 2000 binds to the viral envelope on contact, thereby disrupting the initial binding and fusion steps of HIV infection. PRO 2000 is also active against other STD pathogens, including herpes simplex virus (HSV) types 1 and 2, Chlamydia trachomatis, and Neisseria gonorrhoeae.
PRO 2000 Gel was recently shown to protect monkeys from infection by an AIDS-causing virus. In a small study coordinated by the British Medical Research Council (MRC), intravaginal application of PRO 2000 Gel reduced the infection rate in female rhesus macaques exposed to a high dose of an HIV-like virus. Vaginally applied PRO 2000 Gel was also shown to protect mice completely from vaginal HSV-2 infection. These promising results offer hope that PRO 2000 Gel could protect women from both viruses. Interestingly, PRO 2000 Gel was also found to be contraceptive in rabbits. Surveys indicate that many women would prefer a product with both antimicrobial and contraceptive activity.
Phase I clinical trials to assess the safety and tolerability of PRO 2000 Gel in healthy, sexually abstinent women were completed in 1997. The studies were conducted at the Institute of Tropical Medicine in Antwerp, Belgium and at St. Mary's Hospital in London, England, the latter with support from the MRC. Each double-blind study involved approximately 36 healthy female volunteers who administered either PRO 2000 Gel or a placebo gel intravaginally for up to two weeks. No serious adverse events were reported in either study, and the gels were considered safe and well tolerated. In addition, there was no evidence for systemic absorption of PRO 2000 following vaginal gel application. Importantly, PRO 2000 Gel did not cause microscopic inflammation, which might increase the risk of HIV infection. By contrast, a marketed nonoxynol-9 spermicide was found to cause microscopic inflammation in a similar study.
Procept is now poised to initiate a second phase of clinical testing which will involve a larger and more diverse group of women. An expanded safety study is scheduled to begin shortly in the U.S. and South Africa, with support from the National Institute of Allergy and Infectious Diseases (NIAID). The U. S. Food and Drug Administration (FDA) has allowed this trial to proceed following review of an Investigational New Drug Application (IND) filed by Procept. Additional clinical trials are also being discussed with the MRC. If warranted, a large clinical trial will be conducted to evaluate the safety and protective efficacy of PRO 2000 Gel in women at high risk for HIV infection. Procept believes that the product is well positioned to attract government support for this pivotal study. A recent article in the trade journal Scrip concluded that PRO 2000 Gel is the leading new microbicide in commercial development.
In summary stick with it,, people will be drooling over procept next year and my friend i aint monkeying around. |
